BNB Plus Corp. has outlined a strategy focused on disciplined and strategic accumulation of BNB tokens, aiming to strengthen its digital asset treasury and enhance long-term value creation. The company plans to maintain its accumulation strategy and integrate DeFi-based and native Binance yield opportunities into its operating and treasury framework, with the objective of generating durable yield, improving balance-sheet productivity, and driving shareholder value. Additionally, BNB Plus Corp. will continue its operations in biotechnology through its subsidiary LineaRx, which is expected to narrow losses and approach profitability. The company has also launched a new corporate website and refreshed its branding to reflect its dual mandate as both a biotechnology operator and a corporate holder of BNB tokens.